Company Description
Kyverna Therapeutics, Inc., clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.
The company’s lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome and myasthenia gravis that is in phase 2 clinical trial; and for lupus nephritis.
It is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing, as well as KYV-201, an allogeneic CD19 CAR T-cell product candidate.
It has a license and collaboration agreement with Intellia Therapeutics, Inc. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Feb 8, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Warner Biddle |
Contact Details
Address: 5980 Horton Street, Suite 550 Emeryville, California 94608 United States | |
| Phone | (510) 925-2492 |
| Website | kyvernatx.com |
Stock Details
| Ticker Symbol | KYTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001994702 |
| CUSIP Number | 501976104 |
| ISIN Number | US5019761049 |
| Employer ID | 83-1365441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Warner Biddle | Chief Executive Officer and Director |
| Karen Walker | Chief Technology Officer |
| Ryan Jones M.B.A. | Chief Financial Officer |
| Dr. Tom Van Blarcom Ph.D. | Senior Vice President and Head of Research |
| Tracy Rossin | Senior Vice President of Corporate Affairs and Communications and Investor Relations |
| Cara Bauer Ph.D. | Chief Human Resources Officer |
| Dan Maziasz | Chief Business Officer |
| Dr. Naji H. Gehchan M.B.A., M.D. | Chief Medical and Development Officer |
| Dr. Sham Dholakia DPHIL, M.D. | Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | EFFECT | Notice of Effectiveness |
| Apr 15, 2025 | 424B5 | Filing |
| Apr 14, 2025 | ARS | Filing |
| Apr 14, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |